Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells

Feng Pan, Thomas S. Wingo, Zhigang Zhao, Rui Gao, Hideki Makishima, Guangbo Qu, Li Lin, Miao Yu, Janice R. Ortega, Jiapeng Wang, Aziz Nazha, Li Chen, Bing Yao, Can Liu, Shi Chen, Ophelia Weeks, Hongyu Ni, Brittany Lynn Phillips, Suming Huang, Jianlong Wang & 8 others Chuan He, Guo Min Li, Tomas Radivoyevitch, Iannis Aifantis, Jaroslaw P. MacIejewski, Feng Chun Yang, Peng Jin, Mingjiang Xu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

TET2 is a dioxygenase that catalyses multiple steps of 5-methylcytosine oxidation. Although TET2 mutations frequently occur in various types of haematological malignancies, the mechanism by which they increase risk for these cancers remains poorly understood. Here we show that Tet2-/- mice develop spontaneous myeloid, T- and B-cell malignancies after long latencies. Exome sequencing of Tet2-/- tumours reveals accumulation of numerous mutations, including Apc, Nf1, Flt3, Cbl, Notch1 and Mll2, which are recurrently deleted/mutated in human haematological malignancies. Single-cell-targeted sequencing of wild-type and premalignant Tet2-/- Lin-c-Kit+cells shows higher mutation frequencies in Tet2-/- cells. We further show that the increased mutational burden is particularly high at genomic sites that gained 5-hydroxymethylcytosine, where TET2 normally binds. Furthermore, TET2-mutated myeloid malignancy patients have significantly more mutational events than patients with wild-type TET2. Thus, Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells, suggesting a novel TET2 loss-mediated mechanism of haematological malignancy pathogenesis.

Original languageEnglish (US)
Article number15102
JournalNature Communications
Volume8
DOIs
StatePublished - Jan 1 2017

Fingerprint

stem cells
mutations
Hematopoietic Stem Cells
Stem cells
Hematologic Neoplasms
sequencing
5-Methylcytosine
Dioxygenases
cells
Tumors
pathogenesis
Neoplasms
kits
Cells
Exome
Oxidation
mice
Mutation Rate
tumors
cancer

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Pan, F., Wingo, T. S., Zhao, Z., Gao, R., Makishima, H., Qu, G., ... Xu, M. (2017). Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nature Communications, 8, [15102]. https://doi.org/10.1038/ncomms15102

Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. / Pan, Feng; Wingo, Thomas S.; Zhao, Zhigang; Gao, Rui; Makishima, Hideki; Qu, Guangbo; Lin, Li; Yu, Miao; Ortega, Janice R.; Wang, Jiapeng; Nazha, Aziz; Chen, Li; Yao, Bing; Liu, Can; Chen, Shi; Weeks, Ophelia; Ni, Hongyu; Phillips, Brittany Lynn; Huang, Suming; Wang, Jianlong; He, Chuan; Li, Guo Min; Radivoyevitch, Tomas; Aifantis, Iannis; MacIejewski, Jaroslaw P.; Yang, Feng Chun; Jin, Peng; Xu, Mingjiang.

In: Nature Communications, Vol. 8, 15102, 01.01.2017.

Research output: Contribution to journalArticle

Pan, F, Wingo, TS, Zhao, Z, Gao, R, Makishima, H, Qu, G, Lin, L, Yu, M, Ortega, JR, Wang, J, Nazha, A, Chen, L, Yao, B, Liu, C, Chen, S, Weeks, O, Ni, H, Phillips, BL, Huang, S, Wang, J, He, C, Li, GM, Radivoyevitch, T, Aifantis, I, MacIejewski, JP, Yang, FC, Jin, P & Xu, M 2017, 'Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells', Nature Communications, vol. 8, 15102. https://doi.org/10.1038/ncomms15102
Pan, Feng ; Wingo, Thomas S. ; Zhao, Zhigang ; Gao, Rui ; Makishima, Hideki ; Qu, Guangbo ; Lin, Li ; Yu, Miao ; Ortega, Janice R. ; Wang, Jiapeng ; Nazha, Aziz ; Chen, Li ; Yao, Bing ; Liu, Can ; Chen, Shi ; Weeks, Ophelia ; Ni, Hongyu ; Phillips, Brittany Lynn ; Huang, Suming ; Wang, Jianlong ; He, Chuan ; Li, Guo Min ; Radivoyevitch, Tomas ; Aifantis, Iannis ; MacIejewski, Jaroslaw P. ; Yang, Feng Chun ; Jin, Peng ; Xu, Mingjiang. / Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. In: Nature Communications. 2017 ; Vol. 8.
@article{0a1f3a560cc347e9afe7372122e8f048,
title = "Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells",
abstract = "TET2 is a dioxygenase that catalyses multiple steps of 5-methylcytosine oxidation. Although TET2 mutations frequently occur in various types of haematological malignancies, the mechanism by which they increase risk for these cancers remains poorly understood. Here we show that Tet2-/- mice develop spontaneous myeloid, T- and B-cell malignancies after long latencies. Exome sequencing of Tet2-/- tumours reveals accumulation of numerous mutations, including Apc, Nf1, Flt3, Cbl, Notch1 and Mll2, which are recurrently deleted/mutated in human haematological malignancies. Single-cell-targeted sequencing of wild-type and premalignant Tet2-/- Lin-c-Kit+cells shows higher mutation frequencies in Tet2-/- cells. We further show that the increased mutational burden is particularly high at genomic sites that gained 5-hydroxymethylcytosine, where TET2 normally binds. Furthermore, TET2-mutated myeloid malignancy patients have significantly more mutational events than patients with wild-type TET2. Thus, Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells, suggesting a novel TET2 loss-mediated mechanism of haematological malignancy pathogenesis.",
author = "Feng Pan and Wingo, {Thomas S.} and Zhigang Zhao and Rui Gao and Hideki Makishima and Guangbo Qu and Li Lin and Miao Yu and Ortega, {Janice R.} and Jiapeng Wang and Aziz Nazha and Li Chen and Bing Yao and Can Liu and Shi Chen and Ophelia Weeks and Hongyu Ni and Phillips, {Brittany Lynn} and Suming Huang and Jianlong Wang and Chuan He and Li, {Guo Min} and Tomas Radivoyevitch and Iannis Aifantis and MacIejewski, {Jaroslaw P.} and Yang, {Feng Chun} and Peng Jin and Mingjiang Xu",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/ncomms15102",
language = "English (US)",
volume = "8",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells

AU - Pan, Feng

AU - Wingo, Thomas S.

AU - Zhao, Zhigang

AU - Gao, Rui

AU - Makishima, Hideki

AU - Qu, Guangbo

AU - Lin, Li

AU - Yu, Miao

AU - Ortega, Janice R.

AU - Wang, Jiapeng

AU - Nazha, Aziz

AU - Chen, Li

AU - Yao, Bing

AU - Liu, Can

AU - Chen, Shi

AU - Weeks, Ophelia

AU - Ni, Hongyu

AU - Phillips, Brittany Lynn

AU - Huang, Suming

AU - Wang, Jianlong

AU - He, Chuan

AU - Li, Guo Min

AU - Radivoyevitch, Tomas

AU - Aifantis, Iannis

AU - MacIejewski, Jaroslaw P.

AU - Yang, Feng Chun

AU - Jin, Peng

AU - Xu, Mingjiang

PY - 2017/1/1

Y1 - 2017/1/1

N2 - TET2 is a dioxygenase that catalyses multiple steps of 5-methylcytosine oxidation. Although TET2 mutations frequently occur in various types of haematological malignancies, the mechanism by which they increase risk for these cancers remains poorly understood. Here we show that Tet2-/- mice develop spontaneous myeloid, T- and B-cell malignancies after long latencies. Exome sequencing of Tet2-/- tumours reveals accumulation of numerous mutations, including Apc, Nf1, Flt3, Cbl, Notch1 and Mll2, which are recurrently deleted/mutated in human haematological malignancies. Single-cell-targeted sequencing of wild-type and premalignant Tet2-/- Lin-c-Kit+cells shows higher mutation frequencies in Tet2-/- cells. We further show that the increased mutational burden is particularly high at genomic sites that gained 5-hydroxymethylcytosine, where TET2 normally binds. Furthermore, TET2-mutated myeloid malignancy patients have significantly more mutational events than patients with wild-type TET2. Thus, Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells, suggesting a novel TET2 loss-mediated mechanism of haematological malignancy pathogenesis.

AB - TET2 is a dioxygenase that catalyses multiple steps of 5-methylcytosine oxidation. Although TET2 mutations frequently occur in various types of haematological malignancies, the mechanism by which they increase risk for these cancers remains poorly understood. Here we show that Tet2-/- mice develop spontaneous myeloid, T- and B-cell malignancies after long latencies. Exome sequencing of Tet2-/- tumours reveals accumulation of numerous mutations, including Apc, Nf1, Flt3, Cbl, Notch1 and Mll2, which are recurrently deleted/mutated in human haematological malignancies. Single-cell-targeted sequencing of wild-type and premalignant Tet2-/- Lin-c-Kit+cells shows higher mutation frequencies in Tet2-/- cells. We further show that the increased mutational burden is particularly high at genomic sites that gained 5-hydroxymethylcytosine, where TET2 normally binds. Furthermore, TET2-mutated myeloid malignancy patients have significantly more mutational events than patients with wild-type TET2. Thus, Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells, suggesting a novel TET2 loss-mediated mechanism of haematological malignancy pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85028922056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028922056&partnerID=8YFLogxK

U2 - 10.1038/ncomms15102

DO - 10.1038/ncomms15102

M3 - Article

VL - 8

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 15102

ER -